VWR International, Thermo Fisher Sign Global Agreement

Article

VWR International has signed a global distribution agreement with Thermo Fisher Scientific.

p>VWR International, a provider of laboratory supplies, equipment and services, has signed a global distribution agreement with Thermo Fisher Scientific.

Thermo Fisher represents one of VWR's most important global suppliers with products supporting all of VWR's customer segments, including pharmaceutical, biotech, industrial, educational, governmental and healthcare.

Source: VWR International

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!
Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

EDQM Announces Digital Version of the European Pharmacopoeia

Susan Haigney
June 26th 2025
Article

EDQM is providing the 12th edition of the European Pharmacopoeia as an all-digital, redesigned, user-friendly issue.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

EMA Conditionally Authorizes Stem Cell Therapy for Blood Cancers

Susan Haigney
June 23rd 2025
Article

The agency has recommended conditional marketing authorization for Zemcelpro (dorocubicel/unexpanded umbilical cord cells) to treat adults with hematological malignancies (blood cell cancers).

Washington, DC, USA - June 24, 2022: The symbol of the U.S. Department of Health and Human Services is seen at the entrance to its headquarters in the Hubert H. Humphrey Building in Washington, DC | Image Credit: © Tada Images - stock.adobe.com.

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

Christopher Cole
June 10th 2025
Article

The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

FDA Appoints New Director of CBER

Susan Haigney
May 7th 2025
Article

Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, has been chosen to lead the Center for Biologics Evaluation and Research at FDA.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

New Cancer Research and Treatment Center in Development in London

Susan Haigney
May 1st 2025
Article

Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

FDA Approves Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Susan Haigney
April 15th 2025
Article

The agency has approved BMS’ Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for unresectable or metastatic hepatocellular carcinoma.

© 2025 MJH Life Sciences

All rights reserved.